• Japanese
  • Korean
  • Chinese
Cover Image

Global Markets for Enzyme Inhibitors -- Focus on Emerging Markets

The global market for enzyme inhibitors was valued at $104.4 billion in 2010 and reached nearly $104.6 billion in 2011. This market is expected to rise at a compound annual growth rate (CAGR) of 4% and reach nearly $127.4 billion by 2016.

The emerging markets segment for enzyme inhibitors was $25.6 billion in 2010 and $27.2 billion in 2011. This segment is expected to rise at a CAGR of 8.7% and reach nearly $41.3 billion through 2016.

Sales of kinase inhibitors in emerging markets were $8.2 billion in 2010 and $9.3 billion in 2011. This sector is expected to grow at a CAGR of 13% and reach nearly $17.1 billion by 2016.

SUMMARY FIGURE
GLOBAL REVENUE OF ENZYME INHIBITORS MARKET, 2009-2016
($ MILLIONS)

Source: BCC Research

STUDY GOALS AND OBJECTIVES

The overall goal of this study is to provide a comprehensive understanding of the current and future characteristics of the global market for enzyme inhibitors.

This report explores present and future strategies within the market for enzyme inhibitors, which includes proton pump inhibitors (PPIs), protease inhibitors, reverse transcriptase inhibitors, kinase inhibitors, statins, aromatase inhibitors, phosphodiesterase type 5 (PDE5) inhibitors, neuraminidase inhibitors, and angiotensin-converting enzyme (ACE) inhibitors. The improvements in the market and the setbacks and needs of the market are discussed in this report. The comparisons, usage, and advantages and disadvantages of different types of enzyme inhibitors are also discussed in this report.

A detailed analysis of the enzyme inhibitors industry structure has been conducted. Revenues are broken down by region. Sales figures are estimated for the five-year forecast period of this report, from 2011 to 2016.

Applications for enzyme inhibitors are also discussed in the report, with emphasis on the usage of the inhibitors in therapeutic categories and various disease sectors. The report also covers significant patents and their allotments in each category.

REASONS FOR DOING THE STUDY

Extensive research in the field of enzyme inhibitors has revealed their target-specific functionality in being able to provide therapeutic treatments for various chronic diseases. Modern industries have now begun to explore the advantages of enzyme inhibitors in their productions and processes. This has led to steady market growth for enzyme inhibitors.

Research and development (R&D) spending, along with increasing competition, patent expirations and new technologies, is directing this to a new level. Although, due to patent expirations, the overall revenue for the market has decreased slightly from 2009 to 2011, new advancements, new product launches and the changing lifestyle will cause the market to grow in the foreseeable future. This study looks at almost all the systems affected by these factors.

Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strengths and weaknesses of each type/technology in light of the new technologies, growing competition and changing customer needs.

CONTRIBUTIONS OF THE STUDY AND INTENDED AUDIENCE

This report provides invaluable information to manufacturers and users of PPIs, protease inhibitors, reverse transcriptase inhibitors, kinase inhibitors, statins, aromatase inhibitors, PDE5 inhibitors, neuraminidase inhibitors, and ACE inhibitors. Pharmaceutical and biotechnology companies, research institutes, and physicians will find this study to be of interest.

SCOPE OF REPORT

The scope of this study encompasses enzyme inhibitors in the pharmaceutical and biotechnology industry. BCC Research analyzes each market and its applications, regulatory environment, technology involved, market projections and market share. Technological issues include the latest trends and developments. Emerging markets for enzyme inhibitors include countries such as India, China, Japan, Korea, Taiwan, Canada, Africa, Australia and New Zealand.

ANALYST CREDENTIALS

The study has been carried out by a team of professionals in the biotechnology industry. The project manager for this project is Shalini S. Dewan, who holds a master's degree in pharmaceutical chemistry and has more than 14 years of industry experience. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Dewan was awarded a Gold Medal by the prime minister of India for her work and has worked with top companies in India and in the U.S.

The lead consultant for this project is Dr. Kapil A. Setia, who has a doctorate in life sciences. She has a number of research publications in her credit, including her thesis on “Studies on Phenotypic Variation, Clonal Propagation and Phyto-chemistry of Tinospora cordifolia (Willd.),” which was given an award of excellence.

Table of Contents

Global Markets for Enzyme Inhibitors -- Focus on Emerging Markets

Chapter - 1: INTRODUCTION - Complimentary

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • CONTRIBUTIONS OF THE STUDY AND INTENDED AUDIENCE
  • SCOPE OF REPORT
  • METHODOLOGY AND INFORMATION SOURCES
  • ANALYST CREDENTIALS
  • RELATED REPORTS
  • BCC ON-LINE SERVICES
  • DISCLAIMER

Chapter - 2: SUMMARY

  • Table Summary: GLOBAL REVENUE OF ENZYME INHIBITORS MARKET, THROUGH 2016
  • Figure Summary: GLOBAL REVENUE OF ENZYME INHIBITORS MARKET, 2009-2016

Chapter - 3: OVERVIEW

  • DEFINITIONS
  • STRUCTURE OF ENZYMES
  • ACTIVATION ENERGY
  • SPECIFICITY
  • ENZYME SUBSTRATE INTERACTION
  • CONDITIONS OF ENZYME ACTION
  • CLASSIFICATION OF ENZYMES
  • REAL-LIFE APPLICATIONS OF ENZYMES
  • NEED FOR ENZYMES IN HUMAN BODY
  • WHAT ARE ENZYME INHIBITORS
  • WHY ENZYME INHIBITION
  • USE OF ENZYME INHIBITORS
  • MECHANISM OF ENZYME INHIBITION
  • TYPES OF ENZYME INHIBITORS
  • CLASSIFICATION OF ENZYME INHIBITORS

Chapter - 4: REGULATORY ASPECTS

  • Table 5: NEW DRUG APPROVALS FOR ENZYME INHIBITORS, 2008-2011
  • Table 6: NEW DRUG APPLICATIONS FOR ENZYME INHIBITORS
  • Table 7: SAFETY ALERTS FOR ENZYME INHIBITORS, 2008-2011

Chapter - 5: MARKET LEADERS AND THEIR PRODUCTS FOR ENZYME INHIBITORS

  • Table 8: LEADING MANUFACTURERS/SUPPLIERS OF PROTON PUMP INHIBITORS
  • Table 9: LEADING MANUFACTURERS/SUPPLIERS OF PROTEASE INHIBITORS
  • Table 10: LEADING MANUFACTURERS/SUPPLIERS OF KINASE INHIBITORS
  • Table 11: LEADING MANUFACTURERS/SUPPLIERS OF STATINS
  • Table 12: LEADING MANUFACTURERS/SUPPLIERS OF AROMATASE INHIBITORS
  • Table 13: LEADING MANUFACTURERS/SUPPLIERS OF REVERSE TRANSCRIPTASE INHIBITORS
  • Table 14: LEADING MANUFACTURERS/SUPPLIERS OF PED5 INHIBITORS
  • Table 15: LEADING MANUFACTURERS/SUPPLIERS OF NEURAMINIDASE INHIBITORS
  • Table 16: LEADING MANUFACTURERS/SUPPLIERS OF ACE INHIBITORS

Chapter - 6: NEW DEVELOPMENTS

  • NEW DRUGS IN CLINICAL TRIALS
    • Table 27: NEW ENZYME INHIBITORS IN CLINICAL TRIALS

Chapter - 7: GLOBAL MARKETS

  • MARKET ANALYSIS
  • MARKET SHARES
  • MARKET BY APPLICATIONS
    • Table 28: GLOBAL MARKET FOR ENZYME INHIBITORS, THROUGH 2016
    • Figure 1: GLOBAL MARKET FOR ENZYME INHIBITORS, 2009-2016

Chapter - 8: EMERGING MARKETS

  • MARKET ANALYSIS
  • MARKET SHARES OF INDUSTRY LEADERS IN EMERGING MARKETS
  • MARKET BY APPLICATIONS
    • Table 56: EMERGING MARKETS FOR ENZYME INHIBITORS, THROUGH 2016
    • Figure 29: EMERGING MARKET FOR ENZYME INHIBITORS, 2009-2016

Chapter - 9: PATENT ANALYSIS

  • PATENTS BY YEAR
  • PATENTS BY TYPE
  • PATENTS BY COMPANY
  • PATENTS BY COUNTRY
  • PATENTS BY ASSIGNEE
    • Table 83: NUMBER OF SIGNIFICANT PATENTS BY YEAR, 2008-2012
    • Figure 56: NUMBER OF PATENTS BY YEAR, 2008-2012
    • Figure 57: NUMBER OF PATENTS BY YEAR, 2008-2012

Chapter - 10: CURRENT SITUATION

  • MARKET CONDITIONS
  • TRENDS AND ISSUES IN ENZYME INHIBITORS MARKET

Chapter - 11: COMPANY PROFILES

  • ABBOTT LABORATORIES
  • AMGEN INC.
  • ASTRAZENECA PLC
  • AUROBINDO PHARMA
  • BAYER HEALTHCARE PHARMACEUTICALS
  • BOEHRINGER INGELHEIM GMBH
  • BRISTOL-MYERS SQUIBB
  • CIPLA LTD.
  • DR. REDDY'S LABORATORIES LTD.
  • EISAI INC.
  • ELI LILLY & CO.
  • ENDO PHARMACEUTICALS
  • GILEAD SCIENCES INC.
  • GLAXOSMITHKLINE PLC
  • GLENMARK GENERICS LTD.
  • HETERO DRUGS LTD.
  • HOFFMAN-LA ROCHE LTD.
  • INCYTE CORP.
  • JOHNSON & JOHNSON
  • LUPIN PHARMACEUTICALS INC.
  • MERCK & CO. INC.
  • MERCK SERONO SA
  • MYLAN LABORATORIES INC.
  • MYLAN LABORATORIES LTD.
  • NOVARTIS AG
  • OSI PHARMACEUTICALS LLC
  • PAR PHARMACEUTICAL COMPANIES INC.
  • PFIZER INC.
  • RANBAXY LABORATORIES LTD.
  • ROXANE LABORATORIES LTD.
  • SANDOZ
  • SANOFI-AVENTIS
  • SANTARUS INC.
  • SUN PHARMACEUTICALS
  • TAKEDA PHARMACEUTICAL CO. LTD.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • VERTEX PHARMACEUTICALS
  • VIIV HEALTHCARE
  • WATSON PHARMACEUTICALS INC.

Chapter - 12: APPENDIX - ABBREVIATIONS

List of Tables

  • Summary Table: GLOBAL REVENUE OF ENZYME INHIBITORS MARKET, THROUGH 2016
  • Table 1: CLASSIFICATION OF ENZYME INHIBITORS
  • Table 2: HISTORY OF DEVELOPMENT OF STATINS
  • Table 3: HISTORY OF DISCOVERY OF PROTEASE INHIBITORS
  • Table 4: DEVELOPMENT OF ACE INHIBITORS
  • Table 5: NEW DRUG APPROVALS FOR ENZYME INHIBITORS, 2008-2011
  • Table 6: NEW DRUG APPLICATIONS FOR ENZYME INHIBITORS
  • Table 7: SAFETY ALERTS FOR ENZYME INHIBITORS, 2008-2011
  • Table 8: LEADING MANUFACTURERS/SUPPLIERS OF PROTON PUMP INHIBITORS
  • Table 9: LEADING MANUFACTURERS/SUPPLIERS OF PROTEASE INHIBITORS
  • Table 10: LEADING MANUFACTURERS/SUPPLIERS OF KINASE INHIBITORS
  • Table 11: LEADING MANUFACTURERS/SUPPLIERS OF STATINS
  • Table 12: LEADING MANUFACTURERS/SUPPLIERS OF AROMATASE INHIBITORS
  • Table 13: LEADING MANUFACTURERS/SUPPLIERS OF REVERSE TRANSCRIPTASE INHIBITORS
  • Table 14: LEADING MANUFACTURERS/SUPPLIERS OF PED5 INHIBITORS
  • Table 15: LEADING MANUFACTURERS/SUPPLIERS OF NEURAMINIDASE INHIBITORS
  • Table 16: LEADING MANUFACTURERS/SUPPLIERS OF ACE INHIBITORS
  • Table 17: CLINICAL TRIALS ENZYME INHIBITORS
  • Table 18: CLINICAL TRIALS OF STATINS
  • Table 19: CLINICAL TRIALS FOR AROMATASE INHIBITORS
  • Table 20: CLINICAL TRIALS FOR REVERSE TRANSCRIPTASE INHIBITORS
  • Table 21: CLINICAL TRIALS FOR PROTEIN KINASE INHIBITORS
  • Table 22: CLINICAL TRIALS FOR PDE5 INHIBITORS
  • Table 23: CLINICAL TRIALS FOR PDE4 INHIBITORS
  • Table 24: CLINICAL TRIALS FOR PROTEASE INHIBITORS
  • Table 25: CLINICAL TRIALS FOR ACE INHIBITORS
  • Table 26: CLINICAL TRIALS FOR PROTON PUMP INHIBITORS
  • Table 27: NEW ENZYME INHIBITORS IN CLINICAL TRIALS
  • Table 28: GLOBAL MARKET FOR ENZYME INHIBITORS, THROUGH 2016
  • Table 29: GLOBAL MARKET FOR PROTON PUMP INHIBITORS, THROUGH 2016
  • Table 30: GLOBAL MARKET FOR PROTEASE INHIBITORS, THROUGH 2016
  • Table 31: GLOBAL MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, THROUGH 2016
  • Table 32: GLOBAL MARKET FOR KINASE INHIBITORS, THROUGH 2016
  • Table 33: GLOBAL MARKET FOR STATINS, THROUGH 2016
  • Table 34: GLOBAL MARKET FOR AROMATASE INHIBITORS, THROUGH 2016
  • Table 35: GLOBAL MARKET FOR PDE5 INHIBITORS, THROUGH 2016
  • Table 36: GLOBAL MARKET FOR NEURAMINIDASE INHIBITORS, THROUGH 2016
  • Table 37: GLOBAL MARKET FOR ACE INHIBITORS, THROUGH 2016
  • Table 38: PROTON PUMP INHIBITOR MARKET SHARES BY REGION, 2010
  • Table 39: PROTEASE INHIBITOR MARKET SHARES BY REGION, 2010
  • Table 40: REVERSE TRANSCRIPTASE INHIBITOR MARKET SHARES BY REGION, 2010
  • Table 41: KINASE INHIBITOR MARKET SHARES BY REGION, 2010
  • Table 42: STATINS INHIBITOR MARKET SHARES BY REGION, 2010
  • Table 43: AROMATASE INHIBITOR MARKET SHARES BY REGION, 2010
  • Table 44: PDE5 INHIBITOR MARKET SHARES BY REGION, 2010
  • Table 45: NEURAMINIDASE INHIBITOR MARKET SHARES BY REGION, 2010
  • Table 46: ACE INHIBITOR MARKET SHARES BY REGION, 2010
  • Table 47: GLOBAL ENZYME INHIBITORS MARKET BY THERAPEUTIC CATEGORIES/ DISEASE SECTORS, THROUGH 2016
  • Table 48: GLOBAL MARKET FOR ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE, THROUGH 2016
  • Table 49: GLOBAL MARKET OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASE, THROUGH 2016
  • Table 50: GLOBAL MARKET OF ENZYME INHIBITORS IN HIV/AIDS, THROUGH 2016
  • Table 51: GLOBAL MARKET OF ENZYME INHIBITORS IN HEPATITIS, THROUGH 2016
  • Table 52: GLOBAL MARKET OF ENZYME INHIBITORS IN VARIOUS CANCERS, THROUGH 2016
  • Table 53: GLOBAL MARKET OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION, THROUGH 2016
  • Table 54: GLOBAL MARKET OF ENZYME INHIBITORS IN OTHER SECTORS, THROUGH 2016
  • Table 55: GLOBAL MARKET SHARE OF ENZYME INHIBITORS BY APPLICATION, 2010
  • Table 56: EMERGING MARKETS FOR ENZYME INHIBITORS, THROUGH 2016
  • Table 57: EMERGING MARKETS FOR PROTON PUMP INHIBITORS, THROUGH 2016
  • Table 58: EMERGING MARKETS FOR PROTEASE INHIBITORS, THROUGH 2016
  • Table 59: EMERGING MARKETS FOR REVERSE TRANSCRIPTASE INHIBITORS, THROUGH 2016
  • Table 60: EMERGING MARKETS FOR KINASE INHIBITORS, THROUGH 2016
  • Table 61: EMERGING MARKETS FOR STATINS, THROUGH 2016
  • Table 62: EMERGING MARKETS FOR AROMATASE INHIBITORS, THROUGH 2016
  • Table 63: EMERGING MARKETS FOR PDE5 INHIBITORS, THROUGH 2016
  • Table 64: EMERGING MARKETS FOR NEURAMINIDASE INHIBITORS, THROUGH 2016
  • Table 65: EMERGING MARKETS FOR ACE INHIBITORS, THROUGH 2016
  • Table 66: EMERGING MARKET SHARES OF PROTON PUMP INHIBITOR MANUFACTURERS, 2010
  • Table 67: EMERGING MARKET SHARES OF PROTEASE INHIBITOR MANUFACTURERS, 2010
  • Table 68: EMERGING MARKET SHARES OF KINASE INHIBITOR MANUFACTURERS, 2010
  • Table 69: EMERGING MARKET SHARES OF STATINS MANUFACTURERS, 2010
  • Table 70: EMERGING MARKET SHARES OF AROMATASE INHIBITOR, 2010
  • Table 71: EMERGING MARKET SHARES OF REVERSE TRANSCRIPTASE INHIBITOR MANUFACTURERS, 2010
  • Table 72: EMERGING MARKET SHARES OF PDE5 INHIBITOR MANUFACTURERS, 2010
  • Table 73: EMERGING MARKET SHARES OF NEURAMINIDASE INHIBITOR MANUFACTURERS, 2010
  • Table 74: EMERGING MARKET SHARES OF ACE INHIBITOR MANUFACTURERS, 2010
  • Table 75: EMERGING MARKETS IN ENZYME INHIBITORS BY THERAPEUTIC CATEGORIES/DISEASE SECTORS, THROUGH 2016
  • Table 76: EMERGING MARKETS OF ENZYME INHIBITORS IN CARDIOVASCULAR DISEASES, THROUGH 2016
  • Table 77: EMERGING MARKETS OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASES, THROUGH 2016
  • Table 78: EMERGING MARKETS OF ENZYME INHIBITORS IN HIV/AIDS, THROUGH 2016
  • Table 79: EMERGING MARKETS OF ENZYME INHIBITORS IN HEPATITIS, THROUGH 2016
  • Table 80: EMERGING MARKETS OF ENZYME INHIBITORS IN VARIOUS CANCERS, THROUGH 2016
  • Table 81: EMERGING MARKETS OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION, THROUGH 2016
  • Table 82: EMERGING MARKETS OF ENZYME INHIBITORS IN OTHER DISEASES, THROUGH 2016
  • Table 83: NUMBER OF SIGNIFICANT PATENTS BY YEAR, 2008-2012
  • Table 84: PATENTS BY TYPE FOR ENZYME INHIBITORS, 2008-2012
  • Table 85: NUMBER OF U.S. PATENTS BY COMPANY FOR ENZYME INHIBITORS, 2008-2012
  • Table 86: TOTAL NUMBER OF U.S. PATENTS BY COUNTRY FOR ENZYME INHIBITORS, 2008-2012
  • Table 87: PATENT SHARES BY COUNTRY FOR INDUSTRIAL ENZYMES, 2008-2012
  • Table 88: PATENTS BY TYPE FOR INDUSTRIAL ENZYMES, 2008-2012

List of Figures

  • Summary Figure: GLOBAL REVENUE OF ENZYME INHIBITORS MARKET, 2009-2016
  • Figure 1: GLOBAL MARKET FOR ENZYME INHIBITORS, 2009-2016
  • Figure 2: GLOBAL MARKET FOR PROTON PUMP INHIBITORS, 2009-2016
  • Figure 3: GLOBAL MARKET FOR PROTEASE INHIBITORS, 2009-2016
  • Figure 4: GLOBAL MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, 2009-2016
  • Figure 5: GLOBAL MARKET FOR KINASE INHIBITORS, 2009-2016
  • Figure 6: GLOBAL MARKET FOR STATINS, 2009-2016
  • Figure 7: GLOBAL MARKET FOR AROMATASE INHIBITORS, 2009-2016
  • Figure 8: GLOBAL MARKET FOR PDE5 INHIBITORS, 2009-2016
  • Figure 9: GLOBAL MARKET FOR NEURAMINIDASE INHIBITORS, 2009-2016
  • Figure 10: GLOBAL MARKET FOR ACE INHIBITORS, 2009-2016
  • Figure 11: PROTON PUMP INHIBITOR MARKET SHARES BY REGION, 2010
  • Figure 12: PROTEASE INHIBITOR MARKET SHARES BY REGION, 2010
  • Figure 13: REVERSE TRANSCRIPTASE INHIBITOR MARKET SHARES BY REGION, 2010
  • Figure 14: KINASE INHIBITOR MARKET SHARES BY REGION, 2010
  • Figure 15: STATINS INHIBITOR MARKET SHARES BY REGION, 2010
  • Figure 16: AROMATASE INHIBITOR MARKET SHARES BY REGION, 2010
  • Figure 17: PDE5 INHIBITOR MARKET SHARES BY REGION, 2010
  • Figure 18: NEURAMINIDASE INHIBITOR MARKET SHARES BY REGION, 2010
  • Figure 19: ACE INHIBITOR MARKET SHARES BY REGION, 2010
  • Figure 20: GLOBAL ENZYME INHIBITORS MARKET BY THERAPEUTIC CATEGORIES/ DISEASE SECTORS, 2009-2016
  • Figure 21: GLOBAL MARKET OF ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE, 2009-2016
  • Figure 22: GLOBAL MARKET OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASE, 2009-2016
  • Figure 23: GLOBAL MARKET OF ENZYME INHIBITORS IN HIV/AIDS, 2009-2016
  • Figure 24: GLOBAL MARKET OF ENZYME INHIBITORS IN HEPATITIS, 2009-2016
  • Figure 25: GLOBAL MARKET OF ENZYME INHIBITORS IN VARIOUS CANCERS, 2009-2016
  • Figure 26: GLOBAL MARKET OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION, 2009-2016
  • Figure 27: GLOBAL MARKET OF ENZYME INHIBITORS IN OTHER SECTORS, 2009-2016
  • Figure 28: GLOBAL MARKET SHARE OF TECHNICAL ENZYMES, 2010
  • Figure 29: EMERGING MARKET FOR ENZYME INHIBITORS, 2009-2016
  • Figure 30: EMERGING MARKETS FOR PROTON PUMP INHIBITORS, 2009-2016
  • Figure 31: EMERGING MARKETS FOR PROTEASE INHIBITORS, 2009-2016
  • Figure 32: EMERGING MARKETS FOR REVERSE TRANSCRIPTASE INHIBITORS, 2009-2016
  • Figure 33: EMERGING MARKETS FOR KINASE INHIBITORS, 2009-2016
  • Figure 34: EMERGING MARKETS FOR STATINS, 2009-2016
  • Figure 35: EMERGING MARKETS FOR AROMATASE INHIBITORS, 2009-2016
  • Figure 36: EMERGING MARKETS FOR PDE5 INHIBITORS, 2009-2016
  • Figure 37: EMERGING MARKETS FOR NEURAMINIDASE INHIBITORS, 2009-2016
  • Figure 38: EMERGING MARKETS FOR ACE INHIBITORS, 2009-2016
  • Figure 39: EMERGING MARKET SHARES OF PROTON PUMP INHIBITOR MANUFACTURERS, 2010
  • Figure 40: EMERGING MARKETS SHARES OF PROTEASE INHIBITORS MANUFACTURERS, 2010
  • Figure 41: EMERGING MARKET SHARES OF KINASE INHIBITORS MANUACTURERS, 2010
  • Figure 42: EMERGING MARKETS SHARES OF STATINS MANUFACTURERS, 2010
  • Figure 43: EMERGING MARKET SHARES OF AROMATASE INHIBITOR MANUFACTURERS, 2010
  • Figure 44: EMERGING MARKET SHARES OF REVERSE TRANSCRIPTASE MANUFACTURERS, 2010
  • Figure 45: EMERGING MARKET SHARES OF PED5 MANUFACTURERS, 2010
  • Figure 46: EMERGING MARKET SHARES OF NEURAMINIDASE MANUFACTURERS, 2010
  • Figure 47: EMERGING MARKET SHARES OF ACE INHIBITOR MANUFACTURERS, 2010
  • Figure 48: EMERGING MARKETS IN ENZYME INHIBITORS BY THERAPEUTIC CATEGORIES/DISEASE SECTORS
  • Figure 49: EMERGING MARKETS OF ENZYME INHIBITORS IN CARDIOVASCULAR DISEASES, 2009-2016
  • Figure 50: EMERGING MARKETS OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASES, 2009-2016
  • Figure 51: EMERGING MARKETS OF ENZYME INHIBITORS IN HIV/AIDS, 2009-2016
  • Figure 52: EMERGING MARKETS OF ENZYME INHIBITORS IN HEPATITIS, 2009-2016
  • Figure 53: EMERGING MARKETS OF ENZYME INHIBITORS IN VARIOUS CANCERS, 2009-2016
  • Figure 54: EMERGING MARKETS OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION, 2009-2016
  • Figure 55: EMERGING MARKETS OF ENZYME INHIBITORS IN OTHER DISEASES, 2009-2016
  • Figure 56: NUMBER OF PATENTS BY YEAR, 2008-2012
  • Figure 57: NUMBER OF PATENTS BY YEAR, 2008-2012
  • Figure 58: PATENTS BY TYPE FOR ENZYME INHIBITORS, 2008 - 2012
  • Figure 59: TOTAL NUMBER OF U.S. PATENTS BY COUNTRY FOR ENZYME INHIBITORS, 2008 - 2012
  • Figure 60: PATENT SHARES BY COUNTRY FOR ENZYME INHIBITORS, 2008 - 2012
  • Figure 61: PATENTS BY ASSIGNEE FOR INDUSTRIAL ENZYMES, 2008 - 2012
Show More
Pricing
Get Notified
Email me when related reports are published